| 000 | 01799 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516073328.0 | ||
| 264 | 0 | _c20120514 | |
| 008 | 201205s 0 0 eng d | ||
| 022 | _a1932-6203 | ||
| 024 | 7 |
_a10.1371/journal.pone.0028899 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKeravis, Thérèse | |
| 245 | 0 | 0 |
_aDisease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor. _h[electronic resource] |
| 260 |
_bPloS one _c2012 |
||
| 300 |
_ae28899 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdenine _xanalogs & derivatives |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aCyclic AMP _xmetabolism |
| 650 | 0 | 4 |
_aCyclic Nucleotide Phosphodiesterases, Type 4 _xchemistry |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIsoenzymes |
| 650 | 0 | 4 |
_aKidney _xcytology |
| 650 | 0 | 4 |
_aLipopolysaccharides _xpharmacology |
| 650 | 0 | 4 |
_aLupus Erythematosus, Systemic _xdrug therapy |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred CBA |
| 650 | 0 | 4 | _aMice, Inbred MRL lpr |
| 650 | 0 | 4 |
_aPentoxifylline _xtherapeutic use |
| 650 | 0 | 4 |
_aPhosphodiesterase 4 Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aProteinuria _xdrug therapy |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xmetabolism |
| 650 | 0 | 4 |
_aXanthines _xtherapeutic use |
| 700 | 1 | _aMonneaux, Fanny | |
| 700 | 1 | _aYougbaré, Issaka | |
| 700 | 1 | _aGazi, Lucien | |
| 700 | 1 | _aBourguignon, Jean-Jacques | |
| 700 | 1 | _aMuller, Sylviane | |
| 700 | 1 | _aLugnier, Claire | |
| 773 | 0 |
_tPloS one _gvol. 7 _gno. 1 _gp. e28899 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1371/journal.pone.0028899 _zAvailable from publisher's website |
| 999 |
_c21463531 _d21463531 |
||